Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
The Pharmacist’s Guide to Patient Identification, Testing, and Antiviral Use.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended this live CE activity AND received CE/CME credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-21-130-L01-P, or a physician, nurse, laboratory professional or BCIDP statement of credit), you are NOT allowed to also receive credit for the home-study on-demand version of this activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) and the Center for Infectious Disease Research and Policy (CIDRAP)|
The panel discussion will cover ways to integrate rapid diagnostics into antimicrobial stewardship programs, how to utilize the best C. difficile testing modality in practice, and when to incorporate next generation sequencing into clinical decision making.
The target audience for this activity includes physicians, pharmacists, nurses, and clinical laboratory professionals.
At the completion of this activity, the participant will be better able to:
Moderator: Debbie Goff, PharmD, Ohio State University
Panel of Experts:
Brandon Bookstaver, PharmD, University of South Carolina
Ferric Fang, MD, University of Washington
Robin Patel, MD, Mayo Clinic
Katherine Perez, PharmD, Houston Methodist
Release Date: May 4, 2021
Expiration Date: May 4, 2022
ACPE Credit Designation (Pharmacist CE)
This activity is jointly provided by ProCE, LLC, CIDRAP (Center for Infectious
Disease Research and Policy), and SIDP (Society of Infectious Diseases Pharmacists).
ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider
of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-130-H01-P
has been assigned to this home study knowledge-based activity. This CE activity is
approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers.
This CE activity is provided at no cost to participants. Completion of an evaluation
and post-test with a score of 70% or higher is required to receive CE credit. Proof
of completion will be posted in NABP CPE Monitor profiles. No partial credit will
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented
by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is
jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing
Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category
1 Credits™. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity
is 1.25 contact hours.
Clinical Laboratory Professionals CE
The Clinical and Laboratory Standards Institute is approved as a provider of continuing
education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.®
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board
of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases
pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon
successful completion of a post-test and online evaluation. The post-test must be
successfully completed in only one attempt. No partial credit will be given. BCIDP
accreditation begins 5/4/2021 for this activity and is available for one year from
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Marnie Peterson, PharmD, PhD has no relevant conflicts of interest to report.
Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS has disclosed that he has served as a Research advisor (contracted research) for and received consulting fees from Kedrion Biopharma.
Ferric C. Fang, MD has disclosed that he has received consulting fees from 30 Technology.
Debra Goff, PharmD has disclosed that she has served as a Research advisor (contracted research) for Merck and Pfizer, and has received consulting fees from Astellas, Cepheid, and Opgen.
Robin Patel, MD, D(ABMM), FIDSA, FACP, F(AAM) has disclosed that she has received funds for research support from ContraFect, Hylomorph, Shionogi, and TenNor Therapeutics Limited; and has received consulting fees from 1928 Diagnostics, Curetis, Next Gen Diagnostics, PathoQuest, and Specific Diagnostics (paid to her institution).
Katherine K. Perez, PharmD has no relevant conflicts of interest to report.
Kristine Moore, MD, MPH has no relevant conflicts of interest to report.
Maya Peters, MPH has no relevant conflicts of interest to report.
Catherine Harrison, RN, MPH has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Potential conflicts of interest were resolved with a peer review process provided by Kristine Moore, MD, MPH.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This CE activity is supported by an educational grant from BioMérieux.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.